[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625172":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria di Parma","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MPN subtypes","EXPERIMENTAL","Patient will be tested for CCR2 expression on CD34+ cells in order to correlate imaging and flow-cytometry data.",[13],"Diagnostic Test: Diagnosis of MPN subtypes",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Diagnosis of MPN subtypes","Non-invasive imaging method (PET\u002FCT) and flow-cytometry",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Elena Masselli, MD, PhD","CONTACT","+39 0521 906655","elena.masselli@unipr.it",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":32,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Dipartimento di Medicina e Chirurgia","RECRUITING","Parma","Italy","43126","IT",{"type":36,"coordinates":37},"Point",[38,39],10.32618,44.79935,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Elena Masselli","Principal Investigator","100625172","a-new-diagnostic-algorithm-to-non-invasively-track-fibrotic-changes-in-myeloproliferative-neoplasms-based-on-c-c-chemokine-receptor-2-detection-from-flow-cytometry-to-the-development-of-targeted-positron-emission-tomography-molecular-imaging-pre-clinical-studies-and-first-in-human-proof-of-concept-100625172",false,"NCT07419178","A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept","GR-MPN","Inclusion Criteria:\n\n* Diagnosis of ET\u002FPV\u002FprePMF\u002FovertPMF according to the WHO 2016 criteria and of SMF according to the IWG-MRT criteria (with histopathological data).\n* Age \\>= 18 yrs\n* ECOG performance status \\\u003C=3\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreastfeeding\n* Ongoing therapy with immunomodulatory drugs (JAK-inhibitors, interferon).\n* For PET imaging, patients should be off any cytoreductive treatment for at least 3 months.\n* Antiplatelet agents are allowed","ALL","18 Years",{"count":57,"type":58},265,"ESTIMATED","INTERVENTIONAL",[61],"NA","Chronic \"Philadelphia-negative\" myeloproliferative syndromes are chronic blood disorders. They include essential thrombocythemia, polycythemia vera, and myelofibrosis. Myelofibrosis may arise de novo (\"primary myelofibrosis\") or represent the evolution of essential thrombocythemia or polycythemia vera (\"secondary myelofibrosis\").\n\nThe myelofibrotic stage-characterized, as the name implies, by the presence of bone marrow fibrosis (deposition of scar-like tissue)-is generally associated with a more severe and symptomatic disease. To date, the only way to assess fibrotic progression in these disorders is bone marrow biopsy.\n\nThe aim of this project is to evaluate whether the identification, tracking, and quantification of cells expressing a specific receptor (CCR2), a selective biomarker of fibrosis, may allow early and non-invasive identification of the fibrotic stage of the disease through:\n\n* laboratory analysis on a blood sample (using flow cytometry)\n* use in PET-CT (positron emission tomography combined with computed tomography) of a tracer specific for the CCR2 receptor, capable of selectively binding to CCR2-expressing cells (⁶⁸Ga-DOTA-ECL1i).",[64],"Myelofibrosis (MF)",[66,67,68,69,70,71,72,73,74,75],"C-C chemokine receptor 2","Myeloproliferative neoplasms","PET","immunohystochemical assay","early detection of cancer","progression monitoring","therapy response monitoring","MRI","MRS","fluorescence","2026-02-16",{"date":78,"type":79},"2026-02-18","ACTUAL",{"date":81,"type":79},"2023-09-05",{"date":83,"type":58},"2027-04-30",{"name":5,"class":6},1]